KYMR MEXC RealStocks
Own real KYMR shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-14 05:53:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Kymera Therapeutics, Inc. (KYMR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $127.62, with a market capitalization of $10.86B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $61.50 to $142.92. This page covers its latest market performance, valuation, price trends and company information.
$10.86B | |
$126.93 | |
$129.93 | |
$124.66 | |
$127.17 | |
629.54K | |
823.49K | |
-- | |
$142.92 | |
$61.50 | |
-- | |
-- |
Kymera Therapeutics, Inc. (KYMR) last closed at $127.62 as of 2026-11-14 01:00:00, up 0.38% ($0.48) from the previous close of $127.17.
During the latest regular trading session, KYMR traded between $124.66 and $129.93, with a volume of 629.54K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Kymera Therapeutics, Inc. (KYMR) moved from $128.12 to $127.62, representing a decline of 0.39% ($0.50).
The stock traded between $124.22 and $142.92 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 859.46 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 81.2%
KYMR is currently trading at $127.62, placing it 81.2% of the way from its 52-week low of $61.50 to its 52-week high of $142.92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 285 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kymera Therapeutics, Inc. (KYMR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to KYMR, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between KYMR shares and USD.
KYMR Shares to USD
1.00 KYMR shares = 127.623 USD
Calculations are estimates based on the latest available price and are for reference only.